Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences strategic Oncology Affiliate — Arcus Biosciences (NYSE: RCUS) Total Revenues ($M) ($M)
Arcus Biosciences, Inc. (NYSE: RCUS, CIK 0001724521) Form 10-Q / 10-K
Latest, FY2025
33
Period ended Dec 31, 2025
Change on a year earlier
-35.3%
51 in FY2024
History
7 years
Since FY2019
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Strategic Oncology Affiliate — Arcus Biosciences (NYSE: RCUS) Total Revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 33 | -35.3% | Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗ |
| FY2024 | Dec 31, 2024 | 51 | +37.8% | Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗ |
| FY2023 | Dec 31, 2023 | 37 | -2.6% | Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗ |
| FY2022 | Dec 31, 2022 | 38 | -90.1% | Arcus Biosciences (RCUS) Form 10-K (filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 383 | +391.0% | Arcus Biosciences (RCUS) Form 10-K (filed 2024-02-21) ↗ |
| FY2020 | Dec 31, 2020 | 78 | +420.0% | SEC Filing ↗ |
| FY2019 | Dec 31, 2019 | 15 | – | SEC Filing ↗ |
Breakdown
What makes up strategic oncology affiliate — arcus biosciences (nyse: rcus) total revenues ($m)
- Arcus revenue from Gilead — Other collaboration revenue ($M)26 · FY2025
- Arcus total other collaboration revenue ($M)26 · FY2025
- Arcus revenue from Gilead — License & development services (legacy axis, $M)214 · FY2025
- Arcus Biosciences — Total operating expenses ($M)633 · FY2025
- Arcus Biosciences — Operating income (loss) ($M)-386 · FY2025
- Arcus Biosciences — Net income (loss) ($M)-353 · FY2025
- Arcus Biosciences — Total assets ($M)1,139 · FY2025
Cite this data
StockData. (2026). Gilead Sciences Strategic Oncology Affiliate — Arcus Biosciences (NYSE: RCUS) Total Revenues ($M) ($M), annual FY2019–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rcus_rev_tot
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.